ArticleAnnals of surgical oncology2025
ASO Author Reflections: The Landmark Series: Minimally Invasive Pancreatic Resection-Past, Present, and Future.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimally invasive pancreatic resection (MIPR) has emerged as a safe and effective approach for select patients with pancreatic ductal adenocarcinoma (PDAC), particularly for distal pancreatectomy. Ongoing randomized trials such as DIPLOMA 2 × 2 and PORTAL will further clarify its role in pancreatoduodenectomy, especially with robotic assistance. However, widespread adoption depends not only on evidence but also on access to technology and structured training programs. Expanding dedicated training, simulation-based education, and institutional support will be essential to ensure safe implementation. At the same time, emerging technologies such as augmented reality and next-generation robotics may help lower technical thresholds, lower prices, and accelerate adoption. The continued convergence of high-quality evidence, advanced surgical tools, and equitable implementation strategies will be critical to making MIPR a broadly accessible standard for PDAC, improving outcomes without compromising oncologic rigor. Barriers will need to be overcome to continue growth, such as limited availability of robotic platforms, high costs, and disparities in care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.